Stifel reiterates Buy rating on Kymera Therapeutics with new partnership deal, sees weakness as buying opportunity.

From Yahoo Finance: 2025-06-26 10:45:00

Stifel analyst Alex Thompson reiterates Buy rating on Kymera Therapeutics (KYMR) after Sanofi discontinues development of lead IRAK4 degrader KT-474 in favor of next-gen KT-485. New partnership deal with Gilead for CDK2 molecular glue degrader. Kymera to receive up to $85M in upfront and options. Stifel sees any weakness as a buying opportunity. Kymera shares down 2.5% to $45.96.

Source: TheFly

For more information on KYMR, visit Disclaimer & Disclosure. Contact editor for any issues.

See the top stocks recommended by analysts.

Read more: Kymera weakness a buying opportunity, says Stifel